Nuvectis Pharma NVCT
$19.39 −$0.45 (-2.27%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $19.39 0.00%
Open$19.60
Prev close$19.84
Day range$19.02 – $20.18
Volume301.6K
Market cap$666.80M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$31.05M-298.4% YoY
Net profit-$30.07M-303.0% YoY
Diluted EPS-$1.02-131.8% YoY
Free cash flow-$25.28M-462.5% YoY
Operating cash flow-$25.28M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-67.0%
Return on assets-57.2%
Return on invested capital-69.2%
Current ratio9.92
Liabilities / assets10.1%
Cash & investments$140.71M
Net cash (debt)$140.71M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $31.05M | $7.20M | $6.26M | $27.57M | $7.62M |
| Selling and Admin Expenses | $3.68M | $2.51M | $2.15M | $9.42M | $2.53M |
| -General & Admin Expense | $3.68M | $2.51M | $2.15M | $9.42M | $2.53M |
| Research & Development | $27.37M | $4.68M | $4.11M | $18.15M | $5.09M |
| Operating Profit | -$31.05M | -$7.20M | -$6.26M | -$27.57M | -$7.62M |
| Net Non-Operating Interest Income (Expense) | $979,000.00 | $177,000.00 | $210,000.00 | $1.13M | $303,000.00 |
| Non-Operating Interest Income | $979,000.00 | $177,000.00 | $210,000.00 | $1.13M | $303,000.00 |
| Pretax Profit | -$30.07M | -$7.02M | -$6.05M | -$26.44M | -$7.31M |
| Net Profit | -$30.07M | -$7.02M | -$6.05M | -$26.44M | -$7.31M |
| Profit from Continuing Operations | -$30.07M | -$7.02M | -$6.05M | -$26.44M | -$7.31M |
| Net Income to Parent Company | -$30.07M | -$7.02M | -$6.05M | -$26.44M | -$7.31M |
| Other Preferred Stock Dividends | $0.00 | – | – | $2.43M | $0.00 |
| Net Income to Common Stockholders | -$30.07M | -$7.02M | -$6.05M | -$28.87M | -$7.31M |
| Basic EPS | -$1.02 | -$0.30 | -$0.26 | -$1.32 | -$0.31 |
| Diluted EPS | -$1.02 | -$0.30 | -$0.26 | -$1.32 | -$0.31 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $140.84M | $22.38M | $25.40M | $31.71M | $31.71M |
| Total Current Assets | $140.84M | $22.38M | $25.40M | $31.71M | $31.71M |
| Cash and Cash Equivalents & Short-Term Investments | $140.71M | $22.16M | $25.13M | $31.63M | $31.63M |
| -Cash and Cash Equivalents | $140.71M | $22.16M | $25.13M | $31.63M | $31.63M |
| Other Current Assets | $132,000.00 | $216,000.00 | $268,000.00 | $75,000.00 | $75,000.00 |
| Total Non-Current Assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $14.19M | $13.29M | $11.18M | $13.30M | $13.30M |
| Total Current Liabilities | $14.19M | $13.29M | $11.18M | $13.30M | $13.30M |
| Payables | $5.76M | $5.18M | $4.70M | $6.27M | $6.27M |
| -Accounts Payable | $5.76M | $5.18M | $4.70M | $6.27M | $6.27M |
| Current Accrued Expenses | $2.11M | $92,000.00 | $36,000.00 | $115,000.00 | $115,000.00 |
| Total Non-Current Liabilities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Equity | $126.65M | $9.08M | $14.22M | $18.41M | $18.41M |
| Stockholders' Equity | $126.65M | $9.08M | $14.22M | $18.41M | $18.41M |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $269.47M | $121.84M | $119.96M | $118.10M | $118.10M |
| Retained Earnings | -$142.83M | -$112.76M | -$105.74M | -$99.69M | -$99.69M |
| Current Deferred Liabilities | – | $1.39M | – | – | – |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$25.28M | -$4.53M | -$6.51M | -$16.01M | -$3.97M |
| Net cash flow from continuing operations | -$25.28M | -$4.53M | -$6.51M | -$16.01M | -$3.97M |
| Net Income from Continuing Operations | -$30.07M | -$7.02M | -$6.05M | -$26.44M | -$7.31M |
| Change in Working Capital | $2.37M | $780,000.00 | -$2.31M | $4.40M | $1.86M |
| -Change in Payables and Accrued Expense | $2.59M | $1.01M | -$2.12M | $3.05M | -$115,000.00 |
| -Change in Other Current Assets | $84,000.00 | $52,000.00 | -$193,000.00 | -$1,000.00 | $70,000.00 |
| -Change In Other Working Capital | -$307,000.00 | – | – | $1.35M | $1.91M |
| Net cash flow from investing | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Financing Cash Flow | $143.83M | $1.56M | $7,000.00 | $29.11M | $166,000.00 |
| Net Cash Flow from Continuing Financing Activities | $143.83M | $1.56M | $7,000.00 | $29.11M | $166,000.00 |
| Net Common Stock Issuance | $153.10M | $1.57M | $7,000.00 | $31.21M | $248,000.00 |
| Net Other Financing Charges | -$9.41M | – | – | -$2.10M | -$82,000.00 |
| Ending Cash Balance | $140.71M | $22.16M | $25.13M | $31.63M | $31.63M |
| Net Change in Cash | $118.55M | -$2.97M | -$6.50M | $13.10M | -$3.81M |
| Beginning Cash Balance | $22.16M | $25.13M | $31.63M | $18.53M | $35.44M |
| Free Cash Flow | -$25.28M | -$4.53M | -$6.51M | -$16.01M | -$3.97M |
No comments yet — be the first to weigh in on NVCT.
Sign in to join the discussion.